References
1. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis . Published online 9 March 2020. doi:10.1093/cid/ciaa237
2. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial.medRxiv . Published online 10 April 2020:2020.03.22.20040758. doi:10.1101/2020.03.22.20040758
3. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents . Published online 20 March 2020:105949. doi:10.1016/j.ijantimicag.2020.105949
4. WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. N Engl J Med . 2021;384(6):497-511. doi:10.1056/NEJMoa2023184
5. RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med . 2020;383(21):2030-2040. doi:10.1056/NEJMoa2022926
6. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol . doi:10.1038/s41584-020-0372-x
7. FICHA TECNICA DOLQUINE 200 mg COMPRIMIDOS RECUBIERTOS. Summary of Product Characteristics. Accessed July 21, 2021. https://cima.aemps.es/cima/dochtml/ft/74904/FT_74904.html
8. Velasco-González V, Fernández-Araque A, Sainz-Gil M, Jimeno N, Martín LH, Verde Z. Hydroxychloroquine and Potential Drug Interactions in Older Adults. Arch Bronconeumol . 2020;56(10):679-681. doi:10.1016/j.arbres.2020.06.001
9. Aguirre C, García M. Evaluación de la causalidad en las comunicaciones de reacciones adversas a medicamentos. Algoritmo del Sistema Español de Farmacovigilancia. Med Clin (Barc) . 2016;147(10):461-464. doi:10.1016/j.medcli.2016.06.012
10. Brown EG, Wood L WS. The medical dictionary for regulatory activities (MedDRA). Drug Saf . 1999;20:109-117.
11. Faillie J-L. Case–non-case studies: Principle, methods, bias and interpretation. Therapies . 2019;74(2):225-232. doi:10.1016/j.therap.2019.01.006
12. ICH. Introductory Guide for Standardised MedDRA Queries (SMQs) Version 24.0 .; 2021.
13. Norén GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug-drug interaction surveillance. Stat Med . 2008;27(16):3057-3070. doi:10.1002/sim.3247
14. Agencia española de medicamentos y productos sanitarios (AEMPS). La AEMPS informa de la distribución controlada de todo el stock de hidroxicloroquina/cloroquina. Published online 2020.
15. Alvarez A, Cabia L, Trigo C, Bandrés AC, Bestué M. Prescription profile in patients with SARS-CoV-2 infection hospitalised in Aragon, Spain. Eur J Hosp Pharm . 2020;669:ejhpharm-2020-002476. doi:10.1136/ejhpharm-2020-002476
16. Bull-Otterson L, Gray EB, Budnitz DS, et al. Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment — United States, January–June 2020. MMWR Morb Mortal Wkly Rep . 2020;69(35):1210-1215. doi:10.15585/mmwr.mm6935a4
17. Shehab N, Lovegrove M, Budnitz DS. US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, October 2019 Through March 2020. JAMA Intern Med . 2020;180(10):1384. doi:10.1001/jamainternmed.2020.2594
18. Figliozzi S, Masci PG, Ahmadi N, et al. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. Eur J Clin Invest . 2020;50(10):e13362. doi:10.1111/eci.13362
19. Fiehn C, Ness T, Weseloh C, et al. Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review. Z Rheumatol . 2021;80(S1):1-9. doi:10.1007/s00393-020-00785-4
20. Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology . 2015;23(5):231-269. doi:10.1007/S10787-015-0239-Y
21. AEMPS. Información Acerca Del Uso de Hidroxicloroquina Para El Tratamiento de COVID-19 .; 2020.
22. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int . 2020;40(5):998-1004. doi:10.1111/LIV.14435
23. Falcão F, Viegas E, Carmo I, et al. A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: A preliminary report.Eur J Hosp Pharm . Published online 15 January 2021:ejhpharm-2020-002613. doi:10.1136/ejhpharm-2020-002613
24. Dauner DG, Dauner KN. Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic. J Am Pharm Assoc . 2021;61(3):293-298. doi:10.1016/j.japh.2021.01.007
25. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med . 2020;383(21):2041-2052. doi:10.1056/nejmoa2019014
26. Doyno C, Sobieraj DM, Baker WL. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. Clin Toxicol . Published online 2020. doi:10.1080/15563650.2020.1817479
27. Lane JCE, Weaver J, Kostka K, et al. Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol . 2020;2(11):e698-e711. doi:10.1016/S2665-9913(20)30276-9
28. FICHA TECNICA DUPLAXIL 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG. Summary of Product Characteristics. Accessed July 26, 2021. https://cima.aemps.es/cima/dochtml/ft/84048/FT_84048.html
29. Sharma AN, Mesinkovska NA, Paravar T, Jolla L. Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review. doi:10.1016/j.jaad.2020.04.024
30. Hamm BS, Rosenthal LJ. Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae.
31. Garcia P, Revet A, Yrondi A, Rousseau V, Degboe Y, Montastruc F. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study. Drug Saf . 2020;43(12):1315-1322. doi:10.1007/s40264-020-01013-3
32. Medicines Agency E. New product information wording-Extracts from PRAC recommendations on signals.
33. Hazell L, Shakir SAW. Under-Reporting of Adverse Drug Reactions A Systematic Review. Drug Saf . 2006;29(5):385-396.
34. Maciá-Martínez MA, de Abajo FJ, Roberts G, Slattery J, Thakrar B, Wisniewski AFZ. An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies. Drug Saf . 2016;39(1):29-43. doi:10.1007/s40264-015-0351-3
35. Farcaş A, Măhălean A, Bulik NB, Leucuta D, Mogoșan C. New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014–2017.https://doi.org/101080/1751243320181526676 . 2018;11(10):1045-1051. doi:10.1080/17512433.2018.1526676
36. Drugsite Trust. Hydroxychloroquine Drug Interactions - Drugs.com. Accessed March 26, 2020. https://www.drugs.com/drug-interactions/hydroxychloroquine.html
37. Wisniewski AFZ, Bate A, Bousquet C, et al. Good Signal Detection Practices: Evidence from IMI PROTECT. Drug Saf . 2016;39(6):469. doi:10.1007/S40264-016-0405-1
Table 1. Characteristics of the reported cases